Author: Admin

Developer

QuickChek – March 23, 2021

Posted on by Admin



Allegiant Gold Announces Participation in Noble Capital Markets Virtual Road Show Series

Allegiant Gold announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for March 25, 2021.

Research, News & Market Data on Allegiant Gold

Watch recent C-Suite interview with Allegiant Gold CEO Peter Gianulis



ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing

ProMIS Neurosciences announced the completion of an US$7M (CDN$8.75M) private placement of convertible unsecured debentures

Research, News & Market Data on ProMIS Neurosciences


electroCore Announces Exclusive Distribution Agreement with Silvert Medical Nv-Sa.

electroCore Inc. announced it has entered into an agreement whereby Silvert Medical will serve as the exclusive Western European distributor of the gammaCore Sapphire non-invasive vagus nerve stimulator

Research, News & Market Data on electroCore


Lineage Cell Therapeutics Presents Additional Interim Data On Opregen For Dry Amd With Geographic Atrophy

Lineage Cell Therapeutics announced new positive interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen

Research, News & Market Data on Lineage Cell Therapeutics

Watch recent presentation from NobleCon17



Comstock and MCU Commence Philippine Mercury Remediation Operations

Comstock Mining announced that its first international remediation and extraction facility is now in production

Research, News & Market Data on Comstock Mining

Watch recent interview with Comstock Mining CEO Corrado De Gasperis

Stay up to date. Follow us:

Release – Lineage Cell Therapeutics (LCTX) – Presents Additional Interim Data On Opregen For Dry Amd With Geographic Atrophy

Posted on by Admin

 


Lineage Cell Therapeutics Presents Additional Interim Data On Opregen® For Dry Amd With Geographic Atrophy

 

  • Seventy-Five Percent of All Cohort 4 Patients Have Experienced BCVA Increases
  • Visual Acuity Continues to Decline in the Majority of Untreated Eyes
  • No Acute or Delayed Inflammation or Rejection of OpRegen Observed, Even in Patients Treated with a Reduced Immunosuppressive Regimen

CARLSBAD, Calif.–(BUSINESS WIRE)–Mar. 23, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced new positive interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). Additional interim data were collected on all 24 patients enrolled in the study, including the 12 patients treated in Cohort 4, which feature less advanced disease, better baseline visual acuity, and smaller areas of GA.

Overall, 9/12 (75%) of the Cohort 4 patients’ treated eyes were at or above baseline visual acuity at their last assessment, based on per protocol scheduled visits ranging from 3 months to > 2 years post- transplant. Improvements in best corrected visual acuity (BCVA) reached up to +19 letters on an EDTRS chart. In contrast, 9/12 (75%) of the patients’ untreated eyes were below baseline entry values at the same time points. Among the newly reported data, three (50%) of the more recently treated Cohort 4 patients have exhibited marked improvements in BCVA ranging from +7 to +16 letters at their last scheduled assessments of at least 4.5 months. Two additional Cohort 4 patients remained within 2 letters of their baseline values (one each above and below). One patient measured 7 letters below baseline.

Previously reported structural improvements in the retina and decreases in drusen density have continued with evidence of durable engraftment of OpRegen cells in some treated patients now extending to more than 5 years in the earliest treated patients. A trend towards slower GA progression in treated compared to fellow eyes also continued, although significant changes in GA growth over a 3-month period following treatment are not expected. Overall, OpRegen has been well tolerated with no unexpected adverse events or serious adverse events.

“Data collected from the six additional Cohort 4 patients which we treated last fall has reinforced our prior results and further supports that treatment with OpRegen may provide clinically meaningful outcomes in dry AMD patients with GA. Improvements in BCVA have become apparent within a few months after dosing, consistent with the predicted activity of an RPE cell transplant,” stated  Brian M. Culley, Lineage CEO. “If these early indications of a treatment effect are maintained or improve further, it will be another positive indicator for the potential of OpRegen to improve outcomes in this condition. We continue to monitor all patients on study and in the coming months we will be looking in particular for indications of retinal restoration, reductions in the size and growth of the areas of GA, and functional improvement in visual acuity. Further, the multi-year stability of OpRegen transplants, some in excess of 5 years without signs of rejection, is notable for the durability of our allogeneic cell therapy approach, especially as patients did not require long-term immunosuppression.”

As part of an ongoing effort to administer the minimally effective dose and duration of immunosuppression, reflecting the COVID pandemic and age of typical AMD patients while ensuring the survival of OpRegen cells, no immunosuppression was utilized beyond the perioperative period of up to 3 months in Cohort 4 patients. Notably, the one OpRegen patient who had received a modified immunosuppressive regimen at baseline which included no tacrolimus and only mycophenolate mofetil, does not show any signs of acute or delayed inflammation or rejection of OpRegen cells. One other patient was diagnosed with COVID shortly after treatment with OpRegen and all immunosuppression was halted and then reinstated once the patient was asymptomatic. This second patient similarly showed no signs of acute or delayed inflammation or rejection of OpRegen cells. Other than the reduced regiments described above, immunosuppressants have been discontinued as scheduled, typically within 90 days post-operatively, and no cases of acute or delayed rejection or inflammation due to OpRegen have been reported.

Additional details regarding this data will be presented as part of a corporate update by  Mr. Culley at the Benzinga Global Biotech Small Cap conference on 
March 24, 2021 at 
11:50am Eastern Time / 
8:50am Pacific Time.  Mr. Culley will also be participating in a panel entitled “Coming Together to Address Unmet Medical Needs,” on 
March 24, 2021 at 
12:50pm Eastern Time / 
9:50am Pacific Time. Interested investors are encouraged to register for the event in advance: https://www.benzinga.com/events/small-cap/biotech/. The live and archived webcasts from the event will be available on the Events and Presentations section of Lineage’s website. Additional videos are available on the Media page of the Lineage website.

About OpRegen

OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. The study enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (vision from 20/65 to 20/250 with smaller areas of GA). Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study is to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. Additional objectives include the evaluation of the safety of delivery of OpRegen using the Orbit SDS, manufactured by 
Gyroscope Therapeutics, Ltd.

OpRegen is a registered trademark of 
Cell Cure Neurosciences Ltd., a majority-owned subsidiary of 
Lineage Cell Therapeutics, Inc.

About Dry AMD

Dry age-related macular degeneration (AMD) is a leading cause of adult blindness in the developed world. There are two forms of AMD: wet AMD and dry AMD. Dry AMD is the more common of the two types, accounting for approximately 85-90% of cases. Wet AMD is the less common of the two types, accounting for approximately 10-15% of cases. Global sales of the two leading wet AMD therapies were in excess of 
$10 billion in 2019. Nearly all cases of wet AMD begin as dry AMD. Dry AMD typically affects both eyes. There are currently no 
U.S. Food and Drug Administration (FDA) or 
European Medicines Agency (EMA) approved treatment options available for patients with dry AMD.

About Lineage Cell Therapeutics, Inc. 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the expected clinical outcomes of dry AMD patients with GA and the expected timing when indications of retinal and reductions in size and expansion of the areas of GA may become apparent. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the 
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the 
SEC, including Lineage’s most recent Annual Report on Form 10-K filed with the 
SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
([email protected])
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
([email protected])
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or David Schull
[email protected]
[email protected]
(212) 845-4242

Source: Lineage Cell Therapeutics, Inc.

Research coverage of Lineage Cell Therapeutics (LCTX) on Channelchek is provided by Noble Capital Markets, Inc. Please refer to the research disclosures on the most recent LCTX report for more information.

Release – electroCore Inc. (ECOR) – Announces Exclusive Distribution Agreement with Silvert Medical Nv-Sa. For Western Europe

Posted on by Admin


electroCore, Inc. Announces Exclusive Distribution Agreement with Silvert Medical Nv-Sa. For Western Europe

 

ROCKAWAY, N.J., 
March 23, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with Silvert Medical Nv-Sa. (“Silvert Medical”) whereby Silvert Medical will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) to patients suffering from primary headache disorders in 
Belgium, Luxembourg, 
the Netherlands, and 
France.

“Silvert Medical is proud and excited to represent electroCore’s non-invasive and drug-free medical treatment for chronic migraine and cluster headache. gammaCore Sapphire matches our mission of ’Innovation and Solutions for Better Patient Care’ perfectly,” said  Eric Silvert, Owner and Managing Director of Silvert Medical. “Our long-term expertise in pain management and neuromodulation combined with our access to key opinion leaders within our territories such as 
Belgium, Luxembourg, 
the Netherlands, and 
France will help establish a solid and lasting business relationship.”

“We are delighted to collaborate with Silvert Medical as we continue to expand the geographical coverage of our nVNS therapy amongst patients suffering with migraine and cluster headache,” said Iain Strickland, electroCore’s Vice President of European Operations. “Silvert Medical is an experienced medical device supplier and we look forward to supporting them in our common goal of introducing our nVNS therapy, gammaCore Sapphire, in new Western European territories.”

The initial term of the agreement is three years, and it contains customary terms and conditions, including minimum purchase commitments.

About Silvert Medical Nv-Sa.

Belgium, Silvert Medical Nv-Sa brings a wealth of experience, knowledge and keen responsiveness as a medical device supplier and provides innovative and disruptive medical device technologies to the 
Belgium, Luxembourg, 
the Netherlands, and 
France clinical and patient community.

For more information, visit http://www.silvertmedical.com/

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are for the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCore™

gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in 
the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the 
European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

gammaCore is contraindicated for patients with:

  • An active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  • A metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
  • An open wound, rash, infection, swelling, cut, sore, drug patch, or surgical scar(s) on the neck at the treatment location

Safety and efficacy of gammaCore have not been evaluated in the following patients:

  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Pediatric patients (younger than 12 years)
  • Pregnant women
  • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

In the US, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19.

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects in 
Western Europe and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the 
SEC available at www.sec.gov.

Investors:
Rich Cockrell
CG Capital
404-975-4837
[email protected]

Media Contact:
Summer Diaz
electroCore
816-401-6333
[email protected]

Source: electroCore, Inc.

Release – ProMIS Neurosciences (ARFXF)(PMN:CA) – Completes US$7M (CDN$8.75M) Financing

Posted on by Admin


ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors

 

TORONTO, Ontario and CAMBRIDGE, Mass. — March 22, 2021— ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce today the completion of an US$7M (CDN$8.75M) private placement of convertible unsecured debentures (the “Debentures“).

The investors include Mike Gordon of Fenway Sports Group, the Kraft Group, Henry McCance, co-founder of the Cure Alzheimer’s Fund, and Jeremy Sclar of WS Development Group. “After conducting diligence with a number of experts in the field, we are impressed with the tremendous potential of ProMIS Neurosciences and its unique platform of drug candidates to have a profound impact in the fight against Alzheimer’s and other neurodegenerative diseases.  Our group is pleased to provide funding for the next phase of the company’s exciting future”, stated Mike Gordon of Fenway Sports Group.

“We are honored to have the support of such a distinguished group of investors, all of whom are accomplished leaders in the business and life sciences arenas” said Gene Williams, ProMIS Executive Chairman.

Debenture Terms

The Debentures are convertible into ProMIS common shares at the option of the holder at a conversion price of US$0.10 per share and accrue interest at 1% per annum, which is payable annually. At the company’s election, accrued interest may be paid in cash or common shares (such number of shares determined by dividing the interest due by the 5-day volume-weighted average trading price or “VWAP” of the common shares).

The Debenture mature on March 22, 2026. Prior to the maturity date, the Company may force conversion of the Debentures at the conversion price upon raising US$50M in equity and/or debt cumulatively. On the maturity date, the Company may redeem the outstanding principal amount of the Debentures in either cash or common shares (at the then 5-day VWAP less a 10% discount) or a combination thereof at its election. Amounts redeemed in common shares on the Maturity Date will be subject to TSX acceptance.

The investors were granted a right to participate, on a pro rata basis, in subsequent company offerings of equity securities for cash consideration pursuant to a public offering or a private placement.

The Debentures and any common shares issued on conversion are subject to a four-month hold period that expires on July 22, 2021. Net proceeds will be used for working capital and general corporate purposes.

ProMIS plans to accelerate progress toward a number of top priorities, including:

  • Advancing the PMN310 monoclonal antibody, our potential “best in class” next generation Alzheimer’s treatment, into clinical testing;
  • Enhancing our partnering prospects for programs under active discussion by allowing us to invest in additional validation data; 
  • Expanding our portfolio of products and intellectual property into new target areas, using our proprietary discovery platform; 
  • Advancing our partnered diagnostic programs; 
  • Achieving NASDAQ listing;
  • Expanding our Board of Directors; and
  • Expanding our management team, capitalizing on the talent pool in Boston, to support a growing and ambitious scope of activity.

Retirement of our CEO

Finally, a note of great appreciation for our CEO, Dr. Elliot Goldstein.   Elliot, who just turned 70, has announced his intention to retire from a full time role by the end of 2021.   Even though Elliot is irreplaceable, ProMIS has initiated a search for a new CEO to help us achieve our potential.   “Elliot has been a close friend and valued business partner for decades,” said Gene Williams, “without his significant contributions, we would not have been able to take ProMIS from just a great science idea to a company with a growing portfolio of therapies that have the potential to be life-altering for patients.   On behalf of the entire ProMIS community, and patients who in the future may benefit from our therapies, I offer Elliot our sincere thanks and gratitude”.   

“ProMIS Neurosciences was launched six years ago based on a world class scientific platform from our CSO and scientific founder, Dr. Neil Cashman. Playing a key role in this endeavor has been one of the most challenging yet rewarding experiences of my 40 odd years in pharmaceutical drug development. I am delighted for this exciting new phase of the Company”, stated Dr. Elliot Goldstein, ProMIS CEO.

About ProMIS Neurosciences 

ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF. 

Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn. 

For Investor Relations please contact: 

Alpine Equity Advisors 
Nicholas Rigopulos, President
[email protected]
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Source:

ProMIS Neurosciences


Release – Allegiant Gold (AUXXF)(AUAU:CA) – Announces Participation in Noble Capital Markets Virtual Road Show Series

Posted on by Admin


Allegiant Gold Announces Participation in Noble Capital Markets Virtual Road Show Series

 

RENO, NV, March 23 2021 – Allegiant Gold Ltd. (AUAU: TSX-V) (AUXXF: OTCQX) today announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for March 25, 2021.

The virtual road show will feature a corporate presentation from Allegiant President & CEO Peter Gianulis, followed by a Q & A session proctored by Noble Senior Research Analyst Mark Reichman, featuring questions submitted by the audience.

The live broadcast of the virtual road show is scheduled for March 25, 2021, at 1 PM EDT. Registration is free and open to all investors, at any level. Register Here (https://register.gotowebinar.com/register/6363353590282427918)

Noble’s research, as well as news and advanced market data on Allegiant is available on Channelchek.

About Allegiant

Allegiant owns 100% of 10 highly-prospective gold projects in the United States, 7 of which are located in the mining-friendly jurisdiction of Nevada. Four of Allegiant’s projects are farmed-out, providing for cost reductions and cash-flow. Allegiant’s flagship, district-scale Eastside project hosts a large and expanding gold resource and is located in an area of excellent infrastructure. Preliminary metallurgical testing indicates that both oxide and sulphide gold mineralization at Eastside is amenable to heap leaching.

About Noble Capital Markets

Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving underfollowed small / microcap companies through investment banking, wealth management, trading & execution, and equity research activities. Over the past 36 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports. www.noblecapitalmarkets.com email: [email protected]

About Channelchek

Channelchek (.com) is a comprehensive investor-centric portal – featuring more than 6,000 emerging growth companies – that provides advanced market data, independent research, balanced news, video webcasts, exclusive c-suite interviews, and access to virtual road shows. The site is available to the public at every level without cost or obligation. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC / FINRA registered broker-dealer since 1984. channelchek.vercel.app email: [email protected]

ON BEHALF OF THE BOARD
Peter Gianulis
CEO

For more information contact:
Investor Relations
(604) 634-0970 or
1-888-818-1364

[email protected]

Source: Allegiant Gold

Research coverage of Allegiant Gold (AUXXF) on Channelchek is provided by Noble Capital Markets, Inc. Please refer to the research disclosures on the most recent AUXXF report for more information.

How close is the U.S. to Having a Digital Currency?

Posted on by Admin


What’s the Timeline for a U.S. Digital Currency?

 

Investment opportunities related to the adoption of a U.S. digital currency will undoubtedly change fortunes. But will we ever adopt crypto and are we even close? Actions by the Federal Reserve taken last year and a crescendo of recent statements from top officials suggests that it’s in the works. So the question is “When?” “In what form” and “Who stands to benefit from a Fedcoin?”

Central Bank
Digital Currencies (CBDC) Exploratory Phase

The Federal Reserve Bank of Boston has been collaborating with MIT on what they call the Digital Currency Initiative. They have been exploring together the use of existing and new technologies to build and test a digital currency platform. This includes assessing technology trade-offs, building a hypothetical CBDC, building scalable architecture, a cryptographic platform able to meet the needs of a digital U.S. dollar, speed, security, privacy, and flexibility. Separate from its collaboration with MIT the Boston Fed is evaluating other systems to better comprehend the pros and cons of the U.S. banking system supporting a CBDC.

In a panel discussion yesterday for the Bank of International Settlements (March 22, 2021), Fed Chair Powell exposed some of the Fed’s current thinking. He indicated that when it came to a CBDC, the U.S. has “an obligation to be on the cutting edge of understanding the technological challenges.” He also made clear that any expected benefits of a digital dollar wouldn’t rush the project and that the Fed wouldn’t proceed without support from Congress, preferably in the form of legislation.

The Federal Reserve Bank of Boston, Senior Vice President James Cunha who serves as a spokesman for this project has said the Boston Fed and MIT hope to unveil some of their work in the third quarter of 2021. This includes at least two prototype software platforms that could move, store, and settle transactions made with digital dollars. He did not say if either platform uses the blockchain technology that underlies other cryptocurrencies such as Bitcoin or Ethereum. Once the prototypes are released, Cunha said, others will be able to look at what was built and experiment with the open-source code.

The Fed’s work is intended to show what’s possible without taking a position on the major issues that are out of the purview of the Boston Fed.  The issues he says fall under the direction of Congress, the Treasury, and the Federal Reserve Bank. These include whether the Fed itself should host customer accounts, whether anonymity should be permitted, and what protections users would have in case of a cyber-breach or mistaken transaction. Any policy debate and exploration are separate issues. Discovering what can and can’t be done along with the weaknesses and strengths is the role of the Boston Fed; what to do with that information falls on others.

Around
the World

It’s difficult to have a discussion about any major issue of commerce without looking around the world and seeing what U.S. competitors are up to. The most aggressive mover on the CBDC front is China. The CCP is moving fast to develop its own digital currency, the digital Yuan. At the current pace, the Chinese CBDC will be in use at the 2022 Beijing Olympics.  This alone may force some worldwide use of their digital currency.

For its part, the European Central Bank had this to say, “We have not yet decided whether to issue a digital euro. We are currently in a preparation phase: we’re developing the concept, conducting practical experimentation, listening to the views of the broader public and engaging with stakeholders.” There doesn’t seem to be any urgency in the exploration or adoption of a digital Euro, “We will decide whether to launch a digital euro project towards the middle of 2021, in order to be prepared for the possible issuance of a digital euro at some point in the future,” they said.

 In February 2020, the Central Bank of Brazil (BCB) launched its own official payment network, Pix, which allows instant money transfer and QR code scanning. This digital payment method had its soft launch in November 2020. Brazil has scheduled mass adoption of Pix for this year. 

Washington View

The exploratory push of digital currency technology should not be confused with a push to adopt cashless dollars or other current cryptocurrencies. During the same BIS meeting on March 22, US Fed Chair Powell also had this to say about Bitcoin and other traded cryptocurrencies,” “They’re more of an asset for speculation, so they’re not particularly in use as a means of payment. It’s more a speculative asset. It’s essentially a substitute for gold rather than for the dollar.” So he believes that the current state of non-central bank digital currencies is that they are a gold substitute, not a dollar substitute. Gold is a speculative asset against inflation, civil unrest, and other issues of sovereign risk.

For her part, the former Fed Chair and current Treasury Secretary Janet Yellen spoke a month earlier and had this to say about digital currencies, “To the extent it is used, I fear it’s often for illicit finance. It’s an extremely inefficient way of conducting transactions, and the amount of energy that’s consumed in processing those transactions is staggering.”

It would seem clear from both of these statements that they lean away from any currently traded digital currencies.

Impact of Industries

The Fed and other central banks around the world are giving a lot of attention to digital currencies. China seems intent on developing a standard and introducing a digital Yuan early along with some required use. Brazil has already begun its digital payment system, and companies like Facebook that are financially stronger than many countries have plans of introducing their own crypto to the world. This level of disruption is sure to impact industries. There is no ability to clearly see the future, but assuming in the not-so-distant future many of the world’s transactions take place with a digital currency, these are the impacted industries.

Within financial services, facilitating payments is highly profitable for banks; international transactions generate billions in revenue for financial companies. Digital payments could allow a secure and cheap way of sending payments that cut down on the need for verification from third parties and beat the processing times of current bank transfers. The various cryptocurrencies themselves not tied to a central bank could be the most severe victims. Could it be the current speculative favorites whither? Although when the U.S. went off the gold standard, gold still maintained value, the value of various speculative currencies may quickly be undermined by an official “Fedcoin.” The winners could be blockchain companies and others that adopt the technology for non-currency applications. This could include the travel industry, crowdfunding where it helps with cybersecurity risks, and ridesharing could benefit from a less centralized dispatch system. Trucking could be helped by the technology now most thought of for cryptocurrency tracking — there are currently 500 members of BiTA, the blockchain transportation alliance.  Aerospace and defense companies are working with blockchain technology that has the potential to streamline parts inventory and authentication. Real estate and title issues can be improved with the ledger systems of blockchain to improve efficiency and accuracy.

More directly, a central bank digital currency could make consumers’ everyday transactions easier which by itself is stimulative. Money growth comes from the increased velocity of money. Certainly, an increased ability to transact digitally could be very stimulative throughout the economy.

 

Suggested Reading:


Cryptocurrency Gaining Bank’s Acceptance Backed by the Full Faith and Credit of Blockchain



Is the Small Firm Effect for Microcaps Real? Small Cap Names in a Big Crypto Market

 

 

Sources:

 https://www.coindesk.com/video/the-boston-feds-jim-cunha-cbdcs-are-here-and-theyre-real

https://www.ecb.europa.eu/euro/digital_euro/html/index.en.html

https://www.bcb.gov.br/htms/public/inovtec/Currency-in-the-Digital-Era.pdf

https://www.cbinsights.com/research/industries-disrupted-blockchain/#government

https://www.theguardian.com/business/2018/nov/19/why-central-bank-digital-currencies-will-destroy-bitcoin

Great Lakes Dredge & Dock (GLDD) – A Good Win in Alabama

Posted on by Admin

Monday, March 22, 2021

Great Lakes Dredge & Dock (GLDD)
 A Good Win in Alabama

Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The company only’s operating segments is Dredging. Dredging involves the enhancement or preservation of navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand or rock. Its projects portfolio includes Coastal Restoration, Coastal Protection, Port expansion, and others.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Another win…in Alabama. Bids were opened by the USACE late Friday afternoon on the Phase III of Mobile Harbor deepening work. GLDD was the apparent low bidder at $53.9 million, with Manson closely behind at $57.9 million and Weeks lagging at $76.9 million. Interestingly, all of the bids were well below the IGE of $95.7 million. Final award is slated to be announced in late April.

    Solid dredging outlook with backlog at $559 million, and potential infrastructure spending stimulus could create a tailwind.  We would like to correct a misstatement from our last note and highlight that the Boston award of $62 million was included in the 4Q2020 low bids pending award/options total ~$562 million, including $90 million added in January. Two state projects in Louisiana are out for bid …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Sierra Metals (SMTS)(SMT:CA) – Solid 2020 Performance 2021 Estimates Largely Unchanged

Posted on by Admin

Monday, March 22, 2021

Sierra Metals (SMTS)(SMT:CA)
Solid 2020 Performance; 2021 Estimates Largely Unchanged

As of April 24, 2020, Noble Capital Markets research on Sierra Metals is published under ticker symbols (SMTS and SMT:CA). The price target is in USD and based on ticker symbol SMTS. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Sierra Metals Inc is a precious and base metals producer in Latin America. The company acquires, explores, extracts, and produces mineral concentrates consisting of silver, copper, lead, zinc and gold in Mexico and Peru. Its activity includes the operation of the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico. Yauricocha is an underground polymetallic mine using the sublevel block caving and cut-and-fill mining methods. Bolivar is a copper-silver-zinc-gold underground mine using room-and-pillar mining method. The majority of the revenue is earned by selling of the mineral concentrates to its customers in Peru.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Full year financial results. Sierra Metals reported full year 2020 adjusted net income attributable to shareholders of $29.6 million, or $0.18 per share, compared with $13.9 million, or $0.08 per share, in 2019. Adjusted EBITDA increased 48.6% to $97.0 million compared with $65.3 million in the prior year. Our EPS and EBITDA estimates were $0.20 and $101.3 million. Variances to our estimates were attributed to modestly higher expense. Despite the impact of government-mandated shutdowns during the second quarter and work-flow adjustments due to COVID-19, the company posted strong earnings and cash flow growth in 2020.

    Planned expansions.  Management anticipates receipt in the second quarter of the final permit to increase throughput at the Yauricocha mine by 20% to 3,600 tonnes per day. The company recently published preliminary economic assessments for all three mines which support planned expansions and is working toward completion of preliminary feasibility studies. Longer-term expansions could increase …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Bunker Hill Mining (BHLL)(BNKR:CA) – Announces Updated Mineral Resource and Identifies New Silver Exploration Targets

Posted on by Admin


Bunker Hill Announces Updated Mineral Resource and Identifies New Silver Exploration Targets

 

HIGHLIGHTS:

  • Previous 8.8Mt Inferred resource
    significantly upgraded, supporting the rapid restart program:
    • Indicated resource of 4.4Mt
      containing 3.03Moz of silver, 487M lb of zinc, and 176M lb of lead
    • Inferred resource of 5.6Mt
      containing 8.3Moz of silver, 548M lb of zinc, and 312M lb of lead
  • UTZ added new resource with
    successful silver exploration drilling
  • The PEA remains on track for
    completion in early Q2-2021
  • New, near surface silver
    exploration targets to be evaluated in current drilling campaign

TORONTO, March 22, 2021 (GLOBE NEWSWIRE) — Bunker Hill Mining Corporation (the “Company”) (CSE: BNKR) is pleased to report a significant resource increase at Bunker Hill Mine located in Idaho’s Silver Valley, USA. This underpins the Preliminary Economic Assessment (“PEA”), aimed the mine’s rapid restart potential, due to be published in early Q2-2021.

Sam Ash, CEO of Bunker Hill Mining, stated: “We are excited to see the results of our drilling campaign and continued digitization realized in this significant upgrade of the resource at Bunker Hill, building on the maiden resource we published less than a year ago.  This demonstrates the mine’s outstanding mineral potential, which we expect to be reflected in the PEA assessing a rapid restart. This remains on track for delivery in early April. As part of the on-going campaign to add more silver to our resources, we have also identified some exciting new silver exploration targets in the upper levels of the mine which will be evaluated by drilling over the next few weeks”.

The on-going digital modernization program has yielded a three-dimensional model, defining nearly 100 years of mining voids and geology, which increases confidence in the estimation of mineralization. Additional drilling, modern data collection and assaying, quality assurance and quality control protocols, as well as the verification channel sampling program of 2020 has provided the necessary information to increase the confidence and classification of the Newgard, Quill and UTZ mineral resource estimates. The preponderance of data has converted approximately seventy-seven percent (77%) of the Bunker Hill Mineral Resource to the Indicated Mineral Resource category.

The Bunker Hill Mineral Resource, effective March 19, 2021, reported at a zinc cutoff grade of 3.3% is described below:

Bunker Hill Resource Table

Zinc Resources

K Tons

Pb%

Ag opt

Zn%

Indicated

4,410

2.00

0.69

5.52

Inferred

4,569

1.67

0.83

5.66

Lead-Silver Resources

K Tons

Pb%

Ag opt

Zn%

Indicated

–

–

–

–

Inferred

1,050

7.56

4.28

1.50

Total Resources

K Tons

Pb%

Ag opt

Zn%

Indicated

4,410

2.00

0.69

5.52

Inferred

5,618

2.77

1.48

4.88

Mineral Resources are reported at a zinc cutoff grade of 3.3%. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. Mineral Resources are reported in situ and undiluted. Mineral Resources meet the reasonable prospects of eventual economic extraction due to the fact that the entire vertical extents of the mineralization have been developed on mining levels every two-hundred feet. Newgard and Quill were being actively exploited and developed prior to the shutdown of mining operations in 1991. High grade capping was applied to the assays prior to grade estimation. Grades are estimated using Inverse Distance Cubed (ID3) interpolation techniques. Grades were estimated into a regularized 5 ft x 5 ft x 5 ft block model. A bull density of 11.3 cubic feet per ton was applied to the entire mineral resource based upon historic density values from production records at Bunker Hill. Two-hundred sixty-one (261) drillholes, totaling 29,380-feet, containing 5,720 Pb, Zn and Ag assays were used in the determination of mineralization. Assays were composited to 4,483 5-foot composites. Additionally, 4,545 historic production car samples and 394 channel sample verification samples were used for the resource estimate. Historic mining voids, stopes and development drifting have been accounted for in the resource estimate.

Figure 1: Oblique View of
UTZ, Newgard and Quill Mineral Zones Showing Indicated and Inferred
Mineralization
https://www.globenewswire.com/NewsRoom/AttachmentNg/5e639480-0046-4f96-b5e6-6a71046ab75f

Significant New Silver
Exploration Target Identified

New interpretation and analysis based on developments in the geologic model have identified an exciting new silver exploration opportunity in the hanging wall of the Cate Fault in the upper areas of the Bunker Hill Mine.

Silver production at Bunker Hill came largely from discrete Galena-Quartz Veins that formed ore shoots hosted in preferable quartzite beds of the Revett formation. The vein segments are bounded by large normal faults such as the Dull, Kruger and Sullivan Faults, which have down-dropped large blocks of the stratigraphy and veins down to the south, with >4000 ft of collective displacement. The more recent Cate Thrust Fault has then bisected this package of rocks, shifting rocks above the fault >500 ft up to the north.

The 3D modeling has allowed Bunker Hill geologists to project these vein segments back to their position at time of emplacement. The presence of high-grade silver veins such as the historically mined Sierra Nevada Vein in the hanging wall of the Cate Fault demonstrate that the width of the mineralizing system has not been discovered and the southern margin is unknown. The similar grades, thickness and mineralogy of the vein segments across the earlier normal faults shows that the vertical extent of the system was likely at least 4x the down-dip length of the individual veins. A similar set of normal faults, such as the Buckeye Fault, with significant down-to-the-south displacement also exists in the hanging wall of the Cate fault, with Ag-Pb-Zn mineralization indicated by historic and recent drilling in the hanging wall, or down-dropped portions of these faults.

Figure 2: Hanging Wall of
Cate Fault
https://www.globenewswire.com/NewsRoom/AttachmentNg/2a09189f-10be-49f0-884e-c1df4a2b7e1d

To summarize, none of the major faults that were historically thought as controlling ore emplacement actually bound the mineralizing system, and the entire Property is fully within the elevation and mineralogical zonation leading to silver, lead and zinc deposition.

The Cate Fault was the limit of most early mining in the upper parts of Bunker Hill, and it wasn’t until the 1960’s that it was recognized as having post-mineral offset. A few of the first core holes ever drilled in Bunker Hill in 1898 from the 5 Level were directed past the Cate and Buckeye Faults, with impressive results including 12′ @ 42.7% Pb and 18.6 opt Ag in DH-4, but mining largely shifted to below the 9 level after the Kellogg Tunnel was completed, and these holes were never followed up on. Bunker Hill is currently drilling to test these targets, and the holes are intersecting encouraging structures and lithologies similar to what has been modeled. Any mineralization encountered in these holes will be an entirely new vein system for Bunker Hill, not defined, named, mined or incorporated in any prior mine plans or resource estimates. Drill holes have been planned to systematically offset any successful intercepts in the first holes, and drill stations are being prepared to test these targets at appropriate angles and reduced distances. The locations of the targets are such that any mineralization defined with successful drilling could be rapidly incorporated in an update to mine plans or mineral resources.

Figure 3: Planned Drill
Holes from 5 Level at Cate and Buckeye Faults
https://www.globenewswire.com/NewsRoom/AttachmentNg/b9ae78a0-bbf0-427c-a064-0d482390eec3

Note: The reader is cautioned that these are exploration-stage targets, which is speculative in nature, and there is no guarantee of positive drill results defining any economic mineralization.

A video summarizing the digitization process can be viewed at the following link https://youtu.be/8X3FrWfbGl4?t=229 . In addition, further information is available on our newly launched website.

Recent drill results are presented in the tables below.

ZINC INTERCEPTS

Hole 7046

7046

From

To

M

ZnEq (%)

g/t Ag

%Pb

%Zn

99.5

119.0

19.5

4.3

15.7

1.4

2.8

Including

99.5

100.7

1.2

7.9

24

1.8

5.9

103.3

103.8

0.5

12.5

59

4.7

7.2

105.8

107.3

1.5

7.0

21

1.9

5.0

108.5

109.7

1.2

5.5

16

1.5

3.9

113.8

115.2

1.4

10.2

41

4.3

5.7

Hole 7047

7047

From

To

M

ZnEq (%)

g/t Ag

%Pb

%Zn

92.2

93.1

0.9

9.7

9

0.4

9.1

105.6

106.7

1.1

4.8

10

0.6

4.1

Hole 7052

7052

From

To

M

ZnEq (%)

g/t Ag

%Pb

%Zn

20.1

23.6

3.5

2.1

11.3

0.6

1.3

Including

20.1

22.5

21

23.6

9

1.1

4.4

2.9

16

22

0.8

1.3

3.4

1.4

 

7052

From

To

M

ZnEq (%)

g/t Ag

%Pb

%Zn

37.2

44.5

7.3

2.4

7.8

0.5

1.8

Including

37.2

38.1

0.9

2.8

18

1.5

1.1

39.5

39.8

0.3

9.2

26

2.0

6.9

42.2

43.3

1.1

5.7

10

0.5

5.1

43.3

44.5

1.2

4.0

12

0.7

3.2

Hole 7055A

7055A

From

To

M

ZnEq (%)

g/t Ag

%Pb

%Zn

19.4

20.4

1.0

25.0

105

7.8

16.1

Hole 7061

7061

From

To

M

ZnEq (%)

g/t Ag

%Pb

%Zn

11.9

18.1

6.2

7.3

22.6

1.7

5.5

Including

11.9

12.6

0.7

13.5

29

1.7

11.5

14.2

15.2

1

5.4

38

3.5

1.7

15.2

16.5

1.3

6.6

17

1.3

5.2

16.9

17.7

0.8

18.0

48

3.1

14.3

17.7

18.1

0.4

13.4

20

1.4

11.7

SILVER INTERCEPTS

Hole 7046

7046

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

134.1

159.4

25.3

92.3

12.8

1.0

1.2

Including

138.1

139.5

1.4

255.4

38

2.5

3.4

142.6

143.7

1.1

180.5

26

2.6

1.8

148.4

149.3

0.9

212.5

24

2.5

2.8

158.9

159.4

0.5

332.4

65

3.4

4.0

Hole 7052

7052

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

15.7

17.7

2

85.8

15.5

1.3

0.7

Including

15.7

17.1

16.0

17.7

0.3

0.6

219.5

151.5

34

30

2.6

2.8

2.6

0.8

Hole 7052

7052

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

32.9

33.5

0.6

348.3

43

3.98

4.2

Hole 7054

7054

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

0.9

4.2

3.3

337.1

81.7

7.5

0.4

Including

0.9

2.0

1.1

212

51

5

0.1

2.0

2.4

0.4

282.5

72

6.5

0.1

2.4

3.6

1.1

610

149

13.7

0.7

Hole 7054

7054

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

15.8

16.4

0.6

328.9

86

7.6

0.1

Hole 7055A

7055A

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

1.5

2.3

0.8

361.5

92

8.5

0.1

Hole 7064

7064

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

131.7

132.4

0.7

357.2

138

7.0

0.01

*Due to poor recovery and for QA/QC purposes in portions of holes 7054, 7056 and 7063 and for QA/QC purposes, the company chose to report assay results based only
on recovered
footage. Drilled footage is NOT the reported width of the intercepts.

(Reported widths are
intercepted ore lengths and not true widths, as relationships with
intercepted structures and contacts vary. Prices used to calculate Ag and Zn
Eq are as follows: Zn=$1.16/lb, Pb=$0.92/lb, Ag=$20/oz.)

Upcoming Events:

Alliance Global Partners
(A.G.P) Mining Series Fireside Chat
March 23, 2021 @ 8:00am PT / 11:00am ET
Join Us: REGISTER NOW

Mining & Money Online
Connect
March 24, 2021 @ 10:00am PT / 1:00pm ET
Join Us: REGISTER NOW

Technical Information

The diamond drilling program used HQ-size core.  Bunker Hill followed standard QA/QC practices to ensure the integrity of the core and sample preparation through to delivery of the samples to the assay lab.  The drill core was stored in a secure facility, photographed, logged and sampled based on lithologic and mineralogical interpretations.  Standards of certified reference materials, field duplicates and blanks were inserted as samples shipped with the core samples to the lab.

ALS Global was used to provide analytical services and all results comply with both NI 43-101 and industry standards. ALS Global holds an industry standard ISO 17025 accreditation, specifying general requirements for laboratory performance.

The Company advises that it does not propose to base its production decision on a feasibility study of mineral reserves, demonstrating economic and technical viability, and, as a result, there may be an increased uncertainty of achieving any particular level of recovery of minerals or the cost of such recovery, including increased risks associated with developing a commercially mineable deposit. Historically, such projects have a higher risk of economic and technical failure. There is no guarantee that production will begin as anticipated or at all or that anticipated production costs will be achieved. The Company further cautions that a PEA is preliminary in nature. No mining study has been completed. Mineral resources are not mineral reserves and do not have demonstrated economic viability. There is no certainty that the PEA will be realized.

Qualified Person

Mr. Scott E. Wilson, CPG, President of Resource Development Associates Inc. and a consultant to the Company, is an Independent “Qualified Person” as defined by NI 43-101 and is acting at the Qualified Person for the Company. He has reviewed and approved the technical information summarized in this news release.

About Bunker Hill Mining
Corp.

Under new Idaho-based leadership the Bunker Hill Mining Corp, intends to sustainably restart and develop the Bunker Hill Mine as the first step in consolidating a portfolio of North American precious-metal assets with a focus on silver. Information about the Company is available on its website, www.bunkerhillmining.com, or within the SEDAR and EDGAR databases.

For additional information contact:

Sam Ash, President and Chief Executive Officer
+1 208 786 6999
[email protected]

Cautionary Statements

Certain statements in this
news release are forward-looking and involve a number of risks and uncertainties.
Such forward-looking statements are within the meaning of that term in
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, as well as within the meaning of
the phrase ‘forward-looking information’ in the Canadian Securities
Administrators’ National Instrument 51-102 – Continuous Disclosure
Obligations. Forward-looking statements are not comprised of historical
facts. Forward-looking statements include estimates and statements that describe
the Company’s future plans, objectives or goals, including words to the
effect that the Company or management expects a stated condition or result to
occur. Forward-looking statements may be identified by such terms as
“believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”,
“will”, or “plan”. Since forward-looking statements are based on assumptions
and address future events and conditions, by their very nature they involve
inherent risks and uncertainties. Although these statements are based on
information currently available to the Company, the Company provides no
assurance that actual results will meet management’s expectations. Risks,
uncertainties and other factors involved with forward-looking information
could cause actual events, results, performance, prospects and opportunities
to differ materially from those expressed or implied by such forward-looking
information. Forward looking information in this news release includes, but
is not limited to, the Company’s intentions regarding its objectives, goals
or future plans and statements. Factors that could cause actual results to
differ materially from such forward-looking information include, but are not
limited to: the ability to predict and counteract the effects of COVID-19 on
the business of the Company, including but not limited to the effects of
COVID-19 on the price of commodities, capital market conditions, restriction
on labour and international travel and supply chains; failure to identify
mineral resources; failure to convert estimated mineral resources to
reserves; the inability to complete a feasibility study which recommends a
production decision; the preliminary nature of metallurgical test results;
delays in obtaining or failures to obtain required governmental, environmental
or other project approvals; political risks; changes in equity markets;
uncertainties relating to the availability and costs of financing needed in
the future; the inability of the Company to budget and manage its liquidity
in light of the failure to obtain additional financing, including the ability
of the Company to complete the payments pursuant to the terms of the
agreement to acquire the Bunker Hill Mine Complex; inflation; changes in
exchange rates; fluctuations in commodity prices; delays in the development
of projects; capital, operating and reclamation costs varying significantly
from estimates and the other risks involved in the mineral exploration and
development industry; and those risks set out in the Company’s public
documents filed on SEDAR. Although the Company believes that the assumptions
and factors used in preparing the forward-looking information in this news
release are reasonable, undue reliance should not be placed on such
information, which only applies as of the date of this news release, and no
assurance can be given that such events will occur in the disclosed time
frames or at all. The Company disclaims any intention or obligation to update
or revise any forward-looking information, whether as a result of new information,
future events or otherwise, other than as required by law. No stock exchange,
securities commission or other regulatory authority has approved or
disapproved the information contained herein.

Cautionary Note to United
States Investors Concerning Estimates of Measured, Indicated and Inferred
Resources

This press release has
been prepared in accordance with the requirements of the securities laws in
effect in Canada, which differ from the requirements of U.S. securities laws.
Unless otherwise indicated, all resource and reserve estimates included in
this press release have been disclosed in accordance with NI 43-101 and the
Canadian Institute of Mining, Metallurgy, and Petroleum Definition Standards
on Mineral Resources and Mineral Reserves. NI 43-101 is a rule developed by
the Canadian Securities Administrators which establishes standards for all
public disclosure an issuer makes of scientific and technical information
concerning mineral projects. Canadian disclosure standards, including NI
43-101, differ significantly from the requirements of the United States
Securities and Exchange Commission (“SEC”), and resource and reserve
information contained in this press release may not be comparable to similar
information disclosed by U.S. companies. In particular, and without limiting
the generality of the foregoing, the term “resource” does not equate to the
term “reserves”. Under U.S. standards, mineralization may not be classified
as a “reserve” unless the determination has been made that the mineralization
could be economically and legally produced or extracted at the time the
reserve determination is made. The SEC’s disclosure standards normally do not
permit the inclusion of information concerning “measured mineral resources”,
“indicated mineral resources” or “inferred mineral resources” or other
descriptions of the amount of mineralization in mineral deposits that do not
constitute “reserves” by U.S. standards in documents filed with the SEC.
Investors are cautioned not to assume that any part or all of mineral
deposits in these categories will ever be converted into reserves. U.S.
investors should also understand that “inferred mineral resources” have a
great amount of uncertainty as to their existence and great uncertainty as to
their economic and legal feasibility. It cannot be assumed that all or any
part of an “inferred mineral resource” will ever be upgraded to a higher
category. Investors are cautioned not to assume that all or any part of an
“inferred mineral resource” exists or is economically or legally mineable.
Disclosure of “contained ounces” in a resource is permitted disclosure under
Canadian regulations; however, the SEC normally only permits issuers to
report mineralization that does not constitute “reserves” by SEC standards as
in-place tonnage and grade without reference to unit measures. The
requirements of NI 43-101 for disclosure of “reserves” are also not the same
as those of the SEC, and reserves disclosed by the Company in accordance with
NI 43-101 may not qualify as “reserves” under SEC standards. Accordingly,
information concerning mineral deposits contained in our website may not be
comparable with information made public by companies that report in
accordance with U.S. standards.

Source: Bunker Hill Mining

QuickChek – March 22, 2021

Posted on by Admin



Gevo Hires Dr. Paul Bloom as Chief Technology Officer and Chief Innovation Officer

Gevo announced that Dr. Paul Bloom has joined Gevo as its Chief Technology Officer and Chief Innovation Officer.

Research, News & Market Data on Gevo

Watch recent presentation from NobleCon17



Comtech Telecommunications Corp. Awarded Follow-on Order for More Than $1.0 Million for Military X-band SSPAs

Comtech Telecommunications announced it received a contract valued at more than $1.0 million for X-band SSPA/BUCs for transportable military satellite communications ground systems.

Research, News & Market Data on Comtech Telecommunications

Watch recent presentation from NobleCon17



Bunker Hill Announces Updated Mineral Resource and Identifies New Silver Exploration Targets

Bunker Hill Mining reported a significant resource increase at Bunker Hill Mine located in Idaho’s Silver Valley, USA.

News & Market Data on Bunker Hill Mining


Energy Fuels Announces 2020 Results

Energy Fuels announced its financial results for the year ended December 31, 2020.

Research, News & Market Data on Energy Fuels

Watch recent presentation from NobleCon17

Stay up to date. Follow us:

Release – Energy Fuels (UUUU)(EFR:CA) – Announces 2020 Results Including Robust Balance Sheet

Posted on by Admin

 

 


Energy Fuels Announces 2020 Results, Including Robust Balance Sheet, Market Leading U.S. Uranium Production & Upcoming Commencement of Rare Earth Production; Webcast on Tuesday, March 23, 2021

 

LAKEWOOD, Colo., March 22, 2021 /CNW/ – Energy Fuels Inc. (NYSE: UUUU); (TSX: EFR) (“Energy
Fuels” or the “Company”) today reported its financial results for the year ended December 31, 2020. The Company’s annual report on Form 10-K has been filed with the U.S. Securities and Exchange Commission (”
SEC“) and may be viewed on the Electronic Document Gathering and Retrieval System (“EDGAR“) at www.sec.gov/edgar.shtml, on the System for Electronic Document Analysis and Retrieval (“SEDAR“) at www.sedar.com, and on the Company’s website at www.energyfuels.com. Unless noted otherwise, all dollar amounts are in U.S. dollars.

Highlights:

  • Working capital at December 31, 2020 was $40.2 million, a $19.7 million increase over the Company’s $20.5 million working capital balance at December 31, 2019. The Company’s December 31, 2020 working capital balance of $40.2 million included $22.4 million of cash and marketable securities and $27.6 million of inventory, including approximately 690,700 pounds of U.S. origin uranium produced at the Company’s facilities and 1,672,000 pounds of high-purity vanadium in the form of immediately marketable product.
  • Due to our recent share price strength, the Company raised gross proceeds of $30.4 million on its at-the-market equity program between January 1, 2021 and March 18, 2021, at a weighted average price of $5.53 per share, further enhancing the Company’s financial position. With this strong working capital position, the Company is well positioned to react very swiftly to market opportunities as they arise, particularly with respect to any ramp-up of uranium production needed in response to the proposed strategic national U.S. Uranium Reserve (the “Uranium Reserve“), and to fund capital requirements and other expenditures needed for our developing rare earth element (“REE“) business.
  • On October 6, 2020, the Company announced it was debt free, following the full retirement of all of its floating rate convertible unsecured subordinated debentures.
  • For the year, uranium production totaled approximately 196,500 pounds of U3O8, and vanadium production totaled approximately 67,000 pounds of V2O5.
  • On April 13, 2020, the Company announced its entry into the REE business. By October 2020, the Company had produced on a pilot-scale an intermediate REE product (mixed REE carbonate) from natural REE- and uranium-bearing monazite sands at its White Mesa Mill. Significant quantities of monazite are currently mined as a byproduct of heavy mineral sand operations that primarily recover zircon and titanium in the U.S. and elsewhere in the world. In December 2020, the Company announced that it was entering commercial production of mixed REE carbonate in 2021 following the completion of an agreement on December 14, 2020 to purchase a minimum of 2,500 tons of monazite per year for three years from a facility located in Georgia, USA owned by The Chemours Company (“Chemours“).
  • On March 1, 2021, the Company and Neo Performance Materials (“Neo“) announced the launch of a new U.S.-European REE production initiative. The initiative is expected to produce value-added REE products from natural monazite sands. Energy Fuels plans to process the monazite sands into a mixed REE carbonate at its 100% owned White Mesa Mill in Utah and sell this product as feed material for Neo’s value-added separated REE production plant in Europe.
  • On March 9, 2021, the Company announced that the first shipments of natural monazite ore from Chemours had arrived at the Company’s White Mesa Mill. These first shipments mark the beginning of operations for what we believe will become a burgeoning supply chain. This is a key milestone for the Company, as we work to create, refine, and grow a sustainable rare earth supply chain capable of supplying growing demand for clean technologies in the U.S. and Europe.
  • Energy Fuels is also continuing to evaluate developing its own REE separation and other value-added U.S. REE production capabilities at the White Mesa Mill in the future.
  • No material uranium sales were completed during the year, and the Company is strategically maintaining its uranium inventory for future sales in anticipation of higher uranium prices, potentially as a result of the proposed creation of the Uranium Reserve or due to generally improved uranium market conditions.
  • The Company completed no material vanadium sales during the year. At this time, the Company expects to maintain its V2O5 inventory for sale in the future to capitalize on potential future price increases in vanadium markets. Vanadium prices are currently increasing, and as of March 12, 2021, the mid-point spot price of V2O5 in Europe had increased roughly 60% since the end of 2020.
  • The Company had an operating loss of $24.6 million during 2020, compared to $40.6 million during 2019.
  • On December 21, 2020, the U.S. Congress passed an omnibus appropriation bill that included $75 million to create the proposed Uranium Reserve. The President signed the bill into law on December 27, 2020. This funding opens the door for the U.S. government to purchase domestically produced uranium to guard against potential commercial and national security risks presented by the United States’ near total reliance on imported uranium.
  • On September 14, 2020, the U.S. Department of Commerce (“DOC“) obtained Russia’s agreement to extend limits on uranium imports into the U.S. through 2040 under an extended Russian Suspension Agreement (“RSA“). The DOC won important concessions from Russia, including lower quotas, allowing only a portion of the quotas to be used for the sale of U3O8 and conversion, and strict controls on returned feed under Russian enrichment service contracts.
  • On December 21, 2020, the Company published its first Sustainability Report describing its ongoing commitment to the environment, worker health, public safety and social responsibility. The report highlights the Company’s increasing role in combatting climate change through producing and recycling carbon-free energy resources. The Sustainability Report is publicly available on the Company’s website here.

Mark S. Chalmers, Energy
Fuels’ President and CEO, stated:

“2020 was a transformative year for Energy Fuels, as we worked on developing a rare earth business complementary to our core uranium business. As a result, we believe we have clearly emerged as the key U.S. hub for the raw materials that make many clean energy and advanced technologies possible, including uranium, rare earths and vanadium, all of which are considered ‘critical minerals’ by the U.S. government.

“Starting with our core business, Energy Fuels continues to be the leader in U.S. uranium, as we again led the U.S. in uranium production for the 4th year in a row. Although we are maintaining production at reduced levels for now, our three production facilities in Utah, Wyoming and Texas have a combined capacity to produce more uranium than any other U.S. company. We can quickly deploy this capacity toward improved uranium markets or U.S. government purchases for the strategic national Uranium Reserve. We were pleased to see the U.S. government recognize the strategic importance of our industry when Congress appropriated $75 million for the creation of the proposed Uranium Reserve. We believe our facilities are natural candidates to receive a significant portion of this money, as they have long track records of proven, low-cost production from our multiple projects.

“Last year, it became clear that Energy Fuels might hold the key to restoring sustainable, low-cost, domestic rare earth production in the U.S., which has been a priority for the government and private industry for many years. I’m not exaggerating when I say that rare earths at Energy Fuels’ White Mesa Mill in Utah might be the best resource opportunity I’ve encountered in my 45-year mining career. One of the best naturally occurring rare earth minerals, monazite, is currently mined in the U.S. and elsewhere around the world as a byproduct of other metal mining. However, it is all sold to China’s rare earth industry, due to the presence of uranium and other radionuclides. Recovering and managing these radionuclides requires special licenses and expertise, which we have at our White Mesa Mill. We produced an intermediate rare earth carbonate product on a pilot scale at the Mill in October 2020, which was the first rare earth carbonate production from monazite in the U.S. in over twenty years. In 2020, we also began working with Chemours and Neo to jointly develop a fully integrated U.S.-European rare earth supply chain using monazite mined in Georgia by Chemours, processed in Utah by Energy Fuels for the recovery of uranium and an REE carbonate, with the REE carbonate then manufactured by Neo into value-added rare earth products in Europe. In December 2020, we entered into a 3-year supply agreement with Chemours for monazite. And this month, we entered into an agreement in principle, subject to completion of definitive agreements, to sell our mixed rare earth carbonate to Neo, thereby achieving our objective of creating this fully-integrated rare earth supply chain. We expect to commence commercial production of rare earth carbonate at the Mill in April, 2021. I’m proud to say that we’ve accomplished all of this in less than one year, and if we’re successful in ramping up, we will be producing a rare earth product at a more advanced stage than any other U.S. company, which is receiving significant international attention. We look forward to providing further updates on our progress on rare earths.

“Finally, we significantly strengthened our balance sheet in 2020, setting the stage for us to grow our uranium and rare earth businesses. We had $40.2 million of working capital at December 31, 2020, and we paid off all of our debt in October. Our working capital includes 690,700 pounds of uranium valued at $23.79 per pound and 1,672,000 pounds of vanadium valued at $5.11 per pound on our balance sheet. Currently, the uranium spot price sits at $27.40 per pound, which is 15% higher than our balance sheet carrying value, and the vanadium spot price is $8.33 per pound, which is 63% higher than our balance sheet carrying value. We are closely tracking developments in the uranium and vanadium markets to determine when to sell this material. However, today’s markets are having a material positive effect on our financial position, putting us in an excellent position when we choose to monetize some of these inventories.

“There is renewed interest in the uranium sector, our progress on rare earths has exceeded our highest expectations, and vanadium prices are rising. We are off to a fantastic start in 2021, and I am excited to see what 2021 will bring for Energy Fuels and our shareholders.”

Webcast on Tuesday, March
23, 2021 at 4:00 pm ET (2:00 pm MT):

Energy Fuels will be hosting a video webcast on Tuesday, March 23, 2021 at 4:00 pm ET (2:00 pm MT) to discuss its 2020 financial results and other corporate initiatives. To join the webcast, please click on the link below to access the presentation and the viewer-controlled webcast slides:

Energy Fuels’ FY-2020 Results

If you would like to participate in the webcast and ask questions, please dial (888) 664-6392 (toll free in the U.S. and Canada). 

A link to a recorded version of the proceedings will be available on the Company’s website shortly after the webcast by calling (888) 390-0541 (toll free in the U.S. and Canada) and by entering the code 947332#. The recording will be available until April 6, 2021.

Selected Summary Financial
Information:

$000’s, except per share data

Year ended
December 31, 2020

Year ended
December 31, 2019

Year ended
December 31, 2018

Total revenues

$

1,658

$

5,865

$

31,721

Gross profit (loss)

1,658

1,918

16,969

Operating profit (loss)

(24,627)

(40,581)

(21,312)

Net income (loss) attributable to the company

(27,776)

(37,978)

(25,245)

Basic and diluted loss per share

(0.23)

(0.40)

(0.30)

$000’s

As at December 31,
2020

As at December 31,
2019

Financial
Position:

Working capital

$

40,158

$

20,534

Property, plant and equipment, net

23,621

26,203

Mineral properties, net

83,539

83,539

Total assets

183,236

175,720

Total long-term liabilities

13,376

22,475

Outlook

Overview

In response to the proposed establishment of the Uranium Reserve, the Company is evaluating activities aimed towards increasing uranium production at all or some of its production facilities, including the currently operating White Mesa Mill, as well as the Nichols Ranch ISR Facility, the Alta Mesa ISR Facility, La Sal Complex and Pinyon Plain Mine, which are currently on standby.

During 2021, the Company expects to recover uranium at the White Mesa Mill from alternate feed materials. The Company also expects to recover uranium and produce mixed REE carbonate from natural monazite ore during 2021, subject to successful ramp-up. The vanadium pond-return campaign that was conducted in 2019 was brought to a close in early 2020.

Subject to any actions the Company may take in response to the proposed establishment of the U.S. Uranium Reserve, both ISR and conventional uranium recovery is expected to be maintained at reduced levels, as a result of current uranium market conditions, until such time when market conditions improve sufficiently. Until such time that improvement in uranium market conditions is observed or suitable sales contracts can be entered into, the Company expects to defer further wellfield development at its Nichols Ranch Project. In addition, the Company expects to keep the Alta Mesa Project and its conventional mining properties on standby.

The Company is also seeking new sources of revenue, including its emerging REE business, as well as new sources of alternate feed materials and new fee processing opportunities at the White Mesa Mill that can be processed under existing market conditions (i.e., without reliance on current uranium sales prices). The Company will also continue its support of U.S. governmental activities to support the U.S. uranium mining industry, including the proposed establishment of the Uranium Reserve. In addition, the Company is in discussions to potentially sell certain of its non-material properties, although there are currently no binding offers, and there can be no assurance that a sale will be completed or that we will be successful in completing a sale on acceptable terms.

Extraction and Recovery
Activities Overview

During the year ended December 31, 2020, the Company recovered 196,500 pounds of U3O8, all of which were for the account of the Company. The Company also recovered 67,000 pounds of V2O5, all of which were for the account of the Company. The Company expects to recover approximately 30,000 to 60,000 pounds of U3O8 in the year ending December 31, 2021 for its own account, and zero pounds of U3O8 for the account of others. In 2021, the Company also expects to produce approximately 2,000 to 3,000 tons of mixed REE carbonate at the White Mesa Mill, containing approximately 1,000 to 1,600 tons of total rare earth oxides (“TREO“). The Company expects to produce no vanadium in 2021.

The Company has strategically opted not to enter into any uranium sales commitments for 2021. Therefore, subject to the proposed establishment of the Uranium Reserve and general market conditions, all 2021 uranium production is expected to be added to existing inventories, which are expected to total approximately 720,000 to 750,000 pounds of U3O8 at year-end. All V2O5 inventory is expected to be sold on the spot market if prices rise significantly above current levels, but otherwise maintained in inventory. The Company expects to sell all or a portion of its mixed REE carbonate to global separation facilities and/or to stockpile it for future separation at the White Mesa Mill or elsewhere.

ISR Activities

We extracted and recovered approximately 6,000 pounds of U3O8 from the Nichols Ranch ISR Project for the year ended December 31, 2020. The Company expects to produce insignificant quantities of U3O8 in the year ending December 31, 2021 from Nichols Ranch.

As of December 31, 2020, the Nichols Ranch wellfields had nine header houses that previously extracted uranium, and which are now depleted. The Company currently holds 34 fully-permitted, undeveloped wellfields at Nichols Ranch, including four additional wellfields at the Nichols Ranch wellfields, 22 wellfields at the adjacent Jane Dough wellfields, and eight wellfields at the Hank Project, which is fully permitted to be constructed as a satellite facility to the Nichols Ranch Plant.

The Company expects to continue to keep the Alta Mesa Project on standby until such time as improvements in uranium market conditions are observed, the proposed U.S. Uranium Reserve is established, and/or suitable sales contracts can be procured.

Conventional Activities

Conventional Extraction and
Recovery Activities

During the year ended December 31, 2020, the White Mesa Mill recovered 190,500 pounds of U3O8 and 67,000 pounds of V2O5. The Mill also focused on developing its REE recovery business. During 2021, the Company expects to recover approximately 30,000 to 60,000 pounds of U3O8 at the White Mesa Mill, including uranium recovered through the processing of uranium- and REE-bearing natural monazite ore. The Company also expects to produce approximately 2,000 to 3,000 tons of mixed REE carbonate at the Mill, containing approximately 1,000 to 1,600 tons TREO. The Company currently has approximately 127,000 pounds of U3O8 contained in stockpiled alternate feed material and ore inventory that can be recovered in the future for the proposed Uranium Reserve or as general market conditions warrant. In addition, there remains an estimated 1.5 to 3 million pounds of solubilized recoverable V2O5 inventory remaining in the White Mesa Mill’s tailings facility awaiting future recovery, as market conditions may warrant.

Conventional Standby,
Permitting and Evaluation Activities

During the year ended December 31, 2020, standby and environmental compliance activities occurred at the Pinyon Plain Project. Subject to any actions the Company may take in response to the proposed establishment of the Uranium Reserve and general market conditions, during 2021, the Company plans to continue carrying out engineering, metallurgical testing, procurement and construction management activities at its Pinyon Plain Project.

The Company is selectively advancing certain permits at its other major conventional uranium projects, such as the Roca Honda Project, a large, high-grade conventional project in New Mexico. The Company will also maintain required permits at the Company’s conventional projects, including the Sheep Mountain Project, La Sal Complex, and the Whirlwind mines. In addition, the Company will continue to evaluate the Bullfrog Property at its Henry Mountains Project. The Company is also in discussions to potentially sell the Tony M, Daneros, Rim and other non-core conventional assets.

Uranium Sales

During the year ended December 31, 2020, the Company completed no sales of uranium. The Company currently has no remaining contracts, and therefore all existing uranium inventory and future production is fully unhedged to future uranium price increases.

Vanadium Sales

During 2020, the Company completed no sales of vanadium. The Company expects to sell finished vanadium product when justified into the metallurgical industry, as well as other markets that demand a higher purity product, including the aerospace, chemical, and potentially the vanadium battery industries.

Rare Earth Sales

The Company expects to commence commercial production of a mixed REE carbonate in 2021. Subject to successfully ramping-up production of a salable product during 2021, the Company expects to sell some or all of this intermediate REE product to REE separation facilities outside the U.S. To the extent not sold, the Company expects to stockpile mixed REE carbonate at the White Mesa Mill for future separation and other downstream REE processing at the Mill or elsewhere.

The Company also continues to pursue new sources of revenue, including additional alternate feed materials and other sources of feed for the White Mesa Mill.

About Energy Fuels: Energy Fuels is a leading
U.S.-based uranium mining company, supplying U3O8 to
major nuclear utilities. The Company also produces vanadium from certain of its
projects, as market conditions warrant, and expects to commence commercial
production of REE carbonate in 2021. Its corporate offices are in Lakewood, Colorado
near Denver, and all of its assets and employees are in the United States.
Energy Fuels holds three of America’s key uranium production centers: the White
Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project
in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the
only conventional uranium mill operating in the U.S. today, has a licensed
capacity of over 8 million pounds of U3O8 per year, and
has the ability to produce vanadium when market conditions warrant, as well as
REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR
Project is currently on standby and has a licensed capacity of 2 million pounds
of U3O8 per year. The Alta Mesa ISR Project is also
currently on standby. In addition to the above production facilities, Energy
Fuels also has one of the largest NI 43-101 compliant uranium resource
portfolios in the U.S. and several uranium and uranium/vanadium mining projects
on standby and in various stages of permitting and development. The primary
trading market for Energy Fuels’ common shares is the NYSE American under the
trading symbol “UUUU,” and the Company’s common shares are also
listed on the Toronto Stock Exchange under the trading symbol “EFR.”
Energy Fuels’ website is www.energyfuels.com.

Cautionary Note Regarding
Forward-Looking Statements: This
news release contains certain “Forward Looking Information” and
“Forward Looking Statements” within the meaning of applicable United
States and Canadian securities legislation, which may include, but are not limited
to, statements with respect to: production and sales forecasts; costs of
production; scalability, and the Company’s ability and readiness to re-start,
expand or deploy any of its existing projects or capacity to respond to any
improvements in uranium market conditions or in response to the proposed
Uranium Reserve; any expectation regarding any remaining dissolved vanadium in
the White Mesa Mill’s tailings facility solutions; the ability of the Company
to secure any new sources of alternate feed materials or other processing
opportunities at the White Mesa Mill; expected timelines for the permitting and
development of projects; the Company’s expectations as to longer term
fundamentals in the market and price projections; any expectation that the Company
will maintain its position as a leading uranium company in the United States;
any expectation that the proposed Uranium Reserve will be implemented and if
implemented the manner in which it will be implemented and the timing of
implementation; any expectation with respect to timelines to production; any
expectation that Energy Fuels is well-positioned to be a significant
supplier of the uranium needed for the proposed Uranium Reserve; any
expectation that the Company may be able to sell its uranium and vanadium
inventories at potentially higher prices in the future; any expectation that
the White Mesa Mill will be successful in producing REE Carbonate on a
commercial basis; any expectation that Neo will be successful in separating the
White Mesa Mill’s REE Carbonate on a commercial basis; any expectation that
Energy Fuels will be successful in developing U.S. separation, or other
value-added U.S. REE production capabilities at the White Mesa Mill, or
otherwise; any expectation that the Company, Chemours and Neo will be
successful in jointly developing a fully integrated U.S.-European REE supply
chain; any expectation that the Company will be successful in fully integrating
the U.S REE supply chain in the future; any expectation that, if the Company is successful
in ramping up, it will be producing an REE product at a more advanced stage
than any other U.S. company; any expectation that the Company has emerged as
the key U.S. hub for the raw materials that make many clean energy and advanced
technologies possible; any expectation with respect to the future demand for
REEs; any expectation with respect to the quantities of monazite ore to be
acquired by Energy Fuels, the quantities of REE Carbonate to be produced by the
White Mesa Mill or the quantities of contained TREO in the Mill’s REE
carbonate; any expectation that Neo and Energy Fuels will be successful in
completing definitive agreements and hence proceeding with their agreement in
principle; and any expectation that the Company will successfully sell certain
of its non-material properties on acceptable terms or at all. Generally, these
forward-looking statements can be identified by the use of forward-looking
terminology such as “plans,” “expects,” “does not
expect,” “is expected,” “is likely,”
“budgets,” “scheduled,” “estimates,”
“forecasts,” “intends,” “anticipates,” “does
not anticipate,” or “believes,” or variations of such words and
phrases, or state that certain actions, events or results “may,”
“could,” “would,” “might” or “will be
taken,” “occur,” “be achieved” or “have the
potential to.” All statements, other than statements of historical fact,
herein are considered to be forward-looking statements. Forward-looking
statements involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of the Company
to be materially different from any future results, performance or achievements
express or implied by the forward-looking statements. Factors that could cause
actual results to differ materially from those anticipated in these
forward-looking statements include risks associated with: commodity prices and
price fluctuations; processing and mining difficulties, upsets and delays;
permitting and licensing requirements and delays; changes to regulatory
requirements; legal challenges; the availability of sources of alternate feed
materials and other feed sources for the White Mesa Mill; competition from
other producers; public opinion; government and political actions; the
appropriations for the proposed Uranium Reserve not being allocated to that
program and the Uranium Reserve not being implemented; the manner in which the
proposed Uranium Reserve, if established, will be implemented; the Company not
being successful in selling any uranium into the proposed Uranium Reserve at
acceptable quantities or prices, or at all; available supplies of monazite
sands; the ability of the White Mesa Mill to produce REE Carbonate to meet
commercial specifications on a commercial scale at acceptable costs; the
ability of Neo to separate the REE Carbonate produced by the White Mesa Mill to
meet commercial specifications on a commercial scale at acceptable costs;
market factors, including future demand for REEs; the ability of Neo and Energy
Fuels to finalize definitive agreements; and the other factors described under
the caption “Risk Factors” in the Company’s most recently filed
Annual Report on Form 10-K, which is available for review on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com, and on the Company’s website at www.energyfuels.com. Forward-looking statements contained
herein are made as of the date of this news release, and the Company disclaims,
other than as required by law, any obligation to update any forward-looking
statements whether as a result of new information, results, future events,
circumstances, or if management’s estimates or opinions should change, or
otherwise. There can be no assurance that forward-looking statements will prove
to be accurate, as actual results and future events could differ materially
from those anticipated in such statements. Accordingly, the reader is cautioned
not to place undue reliance on forward-looking statements. The Company assumes
no obligation to update the information in this communication, except as
otherwise required by law.

SOURCE Energy Fuels Inc.

For further information: Investor Inquiries: Energy Fuels Inc., Curtis Moore, VP – Marketing and Corporate Development, (303) 974-2140 or Toll free: (888) 864-2125, [email protected],
www.energyfuels.com

Release – Gevo (GEVO) – Hires Dr. Paul Bloom as Chief Technology Officer and Chief Innovation Officer

Posted on by Admin


Gevo Hires Dr. Paul Bloom as Chief Technology Officer and Chief Innovation Officer

 

ENGLEWOOD,
Colorado – March 22, 2021
– Gevo, Inc. (NASDAQ: GEVO), is pleased to announce that Dr. Paul Bloom has joined Gevo as its Chief Technology Officer and Chief Innovation Officer. Dr. Bloom served the last 20 years in a series of commercial and technical roles at Archer Daniels Midland Company (ADM). Most recently, Dr. Bloom was the Vice President of Sustainable Materials and was previously the General Manager of Evolution Chemicals, where he led development and commercialization activities for the company’s portfolio of renewable chemicals. In addition, he had global responsibility for the company’s pipeline of new process technologies and partnerships with the chemical industry.

“I’m pleased to have Paul Bloom join us. He brings strong technical depth, and business development experience, which we expect to use as we develop the renewable chemicals and materials side of our business,” said Dr. Patrick R. Gruber, Gevo’s Chief Executive Officer. Dr. Gruber continued, “Paul has seen what works and what doesn’t in the space of renewable chemicals, plastics, and fuel. We are fortunate to have him join our team.” 

“I’ve evaluated and commercialized multiple technologies through the years. I believe Gevo has excellent technology to tackle greenhouse gas emissions. Drop-in, net-zero hydrocarbon fuel products are desperately needed and will make a difference in the transportation sector. Gevo’s portfolio also contains renewable chemical materials that can address unmet needs for the circular economy. For example, these high-performance, plant-based products could go into the automotive industry, durable goods, and consumer products,” said Dr. Bloom. “The potential, in my opinion, is large to help provide more sustainable alternatives to customers and consumers while delivering superior performance. I’m excited to be part of the Gevo team and look forward to helping Gevo grow,” Dr. Bloom added.

About Gevo

Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel, and diesel fuel, that when burned have potential to yield net-zero greenhouse gas emissions when measured across the full lifecycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their lifecycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented, technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low carbon products such as gasoline components, jet fuel, and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.

Gevo believes that Argonne National Laboratory GREET model is the best available standard of scientific based measurement for life cycle inventory or LCI.

Learn more at Gevo’s website: www.gevo.com

Forward-Looking
Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, without limitation, including the hiring of Dr. Paul Bloom, Gevo’s technology, Gevo’s products, Gevo’s ability to produce products with “net-zero” Greenhouse Gas emissions, and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

 

Investor and Media Contact
+1 720-647-9605
[email protected]

Release – Comtech Telecommunications (CMTL) – Awarded Follow-on Order for More Than $1.0 Million for Military X-band SSPAs

Posted on by Admin


Comtech Telecommunications Corp. Awarded Follow-on Order for More Than $1.0 Million for Military X-band SSPAs

 

MELVILLE, N.Y.–(BUSINESS WIRE)–Mar. 22, 2021– March 22, 2021– Comtech Telecommunications Corp. (NASDAQ: CMTL) announced today, that during its third quarter of fiscal 2021, its subsidiary, Comtech Xicom Technology, Inc., a world leader in high-power amplifiers, received a contract valued at more than $1.0 million for X-band SSPA/BUCs for transportable military satellite communications (“satcom”) ground systems.

X-band is set aside for government satellite service, primarily military applications that require low interference, low rain-fade, and small terminal size, even if data rates are limited. One of the major challenges of X-band is that, unlike other satcom bands, the receive band is adjacent to the transmit band, making it critical that any RF leakage be extremely low to avoid interfering with the receive signal. Xicom’s X-band amplifiers and BUCs are optimized for this challenging low leakage requirement as well as being high in power density, highly efficient and compact. They are ideal for fixed, transportable, manpack, and mobile military applications.

“Comtech is the industry leader in X-band SSPAs and BUCs. We have invested heavily to build out a comprehensive X-band product line to support military fixed and transportable terminals with the most challenging performance and environmental requirements,” said Fred Kornberg, Chairman of the Board and Chief Executive Officer of Comtech Telecommunications Corp. “Our end-customer remains pleased with the outstanding technical performance and reliability of these Comtech BUCs, and we are proud of our track-record on this critical military program.”

Comtech Xicom Technology, Inc., a world leader in high-power amplifiers, manufactures a wide variety of tube-based and solid-state power amplifiers for military and commercial satellite uplink applications. The product range encompasses power levels from 8 W to 3 kW, with frequency coverage in sub-bands within the 2 GHz to 52 GHz spectrum. Amplifiers are available for fixed and ground-based, shipboard and airborne mobile applications. Please visit www.xicomtech.com for more information.

Comtech Telecommunications Corp. is a leader in the global communications market headquartered in Melville, New York. With a passion for customer success, Comtech designs, produces and markets advanced secure wireless solutions to more than 1,000 customers in more than 100 countries. For more information, please visit www.comtechtel.com.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.

Media Contact:

Michael D. Porcelain, President and Chief Operating Officer
Comtech Telecommunications Corp.
631-962-7000

[email protected]

Source: Comtech Telecommunications Corp.